Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Selectis Health (GBCS) Cost of Revenue (2017 - 2025)

Selectis Health's Cost of Revenue history spans 9 years, with the latest figure at $8.5 million for Q3 2025.

  • For Q3 2025, Cost of Revenue rose 12.48% year-over-year to $8.5 million; the TTM value through Sep 2025 reached $32.6 million, up 7.9%, while the annual FY2024 figure was $30.4 million, 3.24% down from the prior year.
  • Cost of Revenue for Q3 2025 was $8.5 million at Selectis Health, up from $8.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $8.9 million in Q4 2021 and bottomed at $3.5 million in Q1 2021.
  • The 5-year median for Cost of Revenue is $7.6 million (2024), against an average of $7.3 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 96.4% in 2022 before it dropped 11.85% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $8.9 million in 2021, then decreased by 2.18% to $8.7 million in 2022, then decreased by 10.66% to $7.7 million in 2023, then grew by 1.61% to $7.9 million in 2024, then rose by 8.29% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for GBCS's Cost of Revenue are $8.5 million (Q3 2025), $8.2 million (Q2 2025), and $8.1 million (Q1 2025).